Novel il-2 sequences and uses thereof

The IL-2 protein sequence with an N-terminal alanine and cysteine residue addresses the challenges of side effects and manufacturing issues, improving IL-2 therapy by enhancing IL-2Rβγ binding and immune response efficacy.

TW202626105APending Publication Date: 2026-07-01ASCENDIS PHARMA ONCOLOGY DIV AS
0 Cites 0 Cited by

Patent Information

Application Number
TW115109647
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-03-11
Filing Date
2021-06-02
Publication Date
2026-07-01

AI Technical Summary

Technical Problem

Existing IL-2 therapies for cancer treatment are limited by severe side effects such as vascular leakage syndrome due to interactions with IL-2Rαβγ, and manufacturing biased IL-2 proteins with cysteine modifications is challenging due to aggregation issues.

Method used

The IL-2 protein sequence of formula Ala - SEQ A - Cys* - SEQ B is developed, where SEQ A and SEQ B have at least 94% sequence identity with SEQ ID NO: 1 and SEQ ID NO: 2, respectively, with an N-terminal alanine residue and a cysteine residue that can form disulfide bridges, enhancing yield and specificity for IL-2Rβγ binding.

Benefits of technology

The modified IL-2 protein increases yield and preferentially binds to IL-2Rβγ, reducing systemic side effects and improving therapeutic efficacy by enhancing immune response against tumors.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to an IL-2 protein sequence of the formula Ala - SEQ A - Cys* - SEQ B (I), wherein SEQ A has at least 94% sequence identity to SEQ ID NO:1; SEQ B has at least 94% sequence identity to SEQ ID NO:2; Ala is an alanine residue; and Cys* is a cysteine residue; to conjugates thereof and their uses in the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art